ResMed Historical Income Statement
| RMD Stock | USD 249.02 0.31 0.12% |
Historical analysis of ResMed income statement accounts such as Other Operating Expenses of 3.5 B, Operating Income of 1.4 B, EBIT of 1.4 B or Ebitda of 1.6 B can show how well ResMed Inc performed in making a profits. Evaluating ResMed income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ResMed's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ResMed Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ResMed Inc is a good buy for the upcoming year.
ResMed |
About ResMed Income Statement Analysis
ResMed Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ResMed shareholders. The income statement also shows ResMed investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ResMed Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts ResMed Inc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of ResMed Inc minus its cost of goods sold. It is profit before ResMed operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ResMed Inc. It is also known as ResMed overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from ResMed Inc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ResMed Inc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from ResMed's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ResMed Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, ResMed's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 4.9 B, whereas Selling And Marketing Expenses is forecasted to decline to about 4.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 2.0B | 2.4B | 2.7B | 2.8B | Total Revenue | 3.6B | 4.2B | 4.7B | 4.9B |
ResMed income statement Correlations
Click cells to compare fundamentals
ResMed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ResMed income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 180.2M | 191.5M | 193.8M | 196.5M | 216.2M | 227.0M | |
| Interest Expense | 40.4M | 24.0M | 22.3M | 47.4M | 45.7M | 48.0M | |
| Total Revenue | 3.0B | 3.2B | 3.6B | 4.2B | 4.7B | 4.9B | |
| Gross Profit | 1.7B | 1.8B | 2.0B | 2.4B | 2.7B | 2.8B | |
| Other Operating Expenses | 2.1B | 2.3B | 2.6B | 3.1B | 3.4B | 3.5B | |
| Operating Income | 809.7M | 903.7M | 1.0B | 1.1B | 1.3B | 1.4B | |
| Ebit | 809.7M | 907.7M | 982.8M | 1.2B | 1.3B | 1.4B | |
| Ebitda | 989.8M | 1.1B | 1.2B | 1.4B | 1.5B | 1.6B | |
| Cost Of Revenue | 1.2B | 1.4B | 1.6B | 1.9B | 2.0B | 2.1B | |
| Total Operating Expenses | 908.7M | 926.7M | 1.0B | 1.2B | 1.3B | 1.4B | |
| Income Before Tax | 733.1M | 883.7M | 960.5M | 1.1B | 1.3B | 1.3B | |
| Total Other Income Expense Net | (76.6M) | (20.0M) | (39.8M) | (30.2M) | (55.1M) | (52.3M) | |
| Net Income | 621.7M | 474.5M | 779.4M | 897.6M | 1.0B | 1.1B | |
| Income Tax Expense | 111.4M | 409.2M | 181.0M | 204.1M | 243.8M | 256.0M | |
| Selling General Administrative | 676.7M | 670.4M | 739.4M | 874.0M | 917.1M | 963.0M | |
| Research Development | 201.9M | 225.3M | 253.6M | 287.6M | 307.5M | 322.9M | |
| Net Income Applicable To Common Shares | 621.7M | 780.4M | 779.4M | 897.6M | 1.0B | 1.1B | |
| Net Income From Continuing Ops | 621.7M | 474.5M | 779.4M | 897.6M | 1.0B | 526.1M | |
| Tax Provision | 111.4M | 409.2M | 181.0M | 204.1M | 243.8M | 188.8M | |
| Interest Income | 63.1M | 34.8M | 43M | 44.7M | 51.4M | 31.4M | |
| Net Interest Income | (39.4M) | (23.6M) | (22.3M) | (47.4M) | (45.7M) | (43.4M) | |
| Reconciled Depreciation | 181.4M | 191.5M | 193.8M | 197.6M | 216.2M | 187.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.416 | Dividend Share 1.97 | Earnings Share 7.55 | Revenue Per Share 32.711 | Quarterly Revenue Growth 0.111 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.